Metropolis Healthcare downgraded to 'Hold' by MarketsMOJO due to high valuation and stagnant growth

Sep 16 2024 07:22 PM IST
share
Share Via
Metropolis Healthcare, a midcap company in the healthcare industry, has been downgraded to 'Hold' by MarketsMojo due to its high management efficiency and healthy financial position. The company has shown positive results in June 2024 and has a bullish trend in the market. However, its long-term growth and expensive valuation are a concern.
Metropolis Healthcare, a midcap company in the hospital and healthcare services industry, has recently been downgraded to a 'Hold' by MarketsMOJO on September 16, 2024. This decision was based on various factors that indicate a neutral stance towards the stock.

One of the main reasons for the downgrade is the company's high management efficiency, with a ROCE (Return on Capital Employed) of 42.43%. This indicates that the company is utilizing its capital effectively to generate profits. Additionally, Metropolis Healthcare has a low Debt to Equity ratio of 0.08 times, which shows a healthy financial position.

The company also showed positive results in June 2024, with its highest operating cash flow of Rs 264.07 crore and lowest debt-to-equity ratio of 0.18 times in the last half-year. Furthermore, its operating profit to interest ratio was the highest at 16.95 times, indicating strong financial management.

Technically, the stock is in a mildly bullish range, with multiple factors such as MACD, Bollinger Band, and KST showing a bullish trend. Moreover, the company has a high institutional holding of 45.68%, which indicates that these investors have better resources and capabilities to analyze the company's fundamentals.

Metropolis Healthcare has also outperformed the market (BSE 500) with a return of 47.20% in the last year, compared to the market's return of 34.97%. However, its long-term growth has been poor, with net sales growing at an annual rate of 9.54% and operating profit at 2.77% over the last 5 years.

The company's valuation is also a concern, with a high ROE (Return on Equity) of 11.7 and a price to book value of 10.1, indicating an expensive stock. Moreover, the stock is currently trading at a premium compared to its average historical valuations.

In conclusion, while Metropolis Healthcare has shown strong financial management and market-beating performance, its poor long-term growth and expensive valuation have led to a 'Hold' rating by MarketsMOJO. Investors should carefully consider these factors before making any investment decisions.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News